Evidence map›Paper›PMID 34990081›Full record

ReviewAdvanced healthcare materials2022

Laponite-Based Nanomaterials for Drug Delivery.

Gita Kiaee, Nikolaos Dimitrakakis, Shabnam Sharifzadeh, Han-Jun Kim, Reginald K Avery, Kamyar Mollozadeh Moghaddam, Reihaneh Haghniaz, Ezgi Pinar Yalcintas, Natan Roberto de Barros, Solmaz Karamikamkar and 3 more

Abstract readReview
In one paragraph

Review in Advanced healthcare materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Poly(Gels (Basel, Switzerland) · 2025
    Article
  9. Article
  10. LaponitePharmaceutics · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gita KiaeeWyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, 02115, USA.
Nikolaos DimitrakakisWyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, 02115, USA.
Shabnam SharifzadehDana-Farber Cancer Institute, Boston, MA, 02115, USA.
Han-Jun KimTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA.ORCID 0000-0001-9238-7238
Reginald K AveryWyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, 02115, USA.
Kamyar Mollozadeh MoghaddamWyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, 02115, USA.
Reihaneh HaghniazTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA.
Ezgi Pinar YalcintasTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA.
Natan Roberto de BarrosTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA.ORCID 0000-0001-8689-4110
Solmaz KaramikamkarTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA.ORCID 0000-0002-6151-1539
Alberto LibanoriDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, CA, 90095, USA.
Ali KhademhosseiniTerasaki Institute for Biomedical Innovation, Los Angeles, CA, 90024, USA.ORCID 0000-0002-2692-1524
Parastoo KhoshakhlaghWyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, 02115, USA.ORCID 0000-0001-8183-2340

Funding

Hemorrhage control in the irreversible anticoagulated patientR01HL137193 · NHLBI · MAYO CLINIC ARIZONA · PI OKLU, RAHMI · 2017 to 2021
$3.0M
Treatment of arterial aneurysms using an injectable biomaterialR01HL140951 · NHLBI · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2018 to 2021
$2.6M
NHLBI NIH HHS R01 HL137193NHLBI NIH HHS R01 HL140951
6 · The paper itself

Abstract

Laponite is a clay-based material composed of synthetic disk-shaped crystalline nanoparticles with highly ionic, large surface area. These characteristics enable the intercalation and dissolution of biomolecules in Laponite-based drug delivery systems. Furthermore, Laponite's innate physicochemical properties and architecture enable the development of tunable pH-responsive drug delivery systems. Laponite's coagulation capacity and cation exchangeability determine its exchange capabilities, drug encapsulation efficiency, and release profile. These parameters are exploited to design highly controlled and efficacious drug delivery platforms for sustained drug release. In this review, they provide an overview of how to design efficient delivery of therapeutics by leveraging the properties and specific interactions of various Laponite-polymer composites and drug moieties.

Indexed as

NanoparticlesNanostructuresDrug Delivery SystemsSilicateslaponiteSilicatesbiomaterialsclay nanoparticlesdrug carriersdrug deliveryLaponitenanotherapeutics

Identifiers

PMID34990081
PMCPMC8986590

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.